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Insomnia and obstructive sleep apnea (OSA) are often both present in patients with
sleep-disordered-breathing (SDB). The coexistence of the two disorders shows an
increase in cumulative morbidity and an overall greater illness severity. There is still
considerable controversy regarding management decisions in this group of patients.
This systematic review focused on more recent evidence regarding treatment of patients
presenting with both clinical entities of comorbid insomnia and OSA (COMISA) in terms
of their management, especially using combinations of positive airway pressure [PAP,
namely aPAP, cPAP, adaptive servo-ventilation (ASV)] and CBTi as well as each one of
these two modalities alone. As a conclusion it is necessary to specifically target distinct
combinations of both insomnia (initial, middle, late) and OSA (mild, moderate, severe)
phenotypes. The present review gives reason to assume that both CBTi and PAP-therapy
are necessary. However, it appears that distinct treatment patterns may suit different
COMISA phenotypes.
Keywords: COMISA, sleep apnea, insomnia, PAP-therapy, cognitive behavioral therapy
INTRODUCTION
Insomnia and obstructive sleep apnea (OSA) are often both present in patients with
sleep-disordered-breathing (SDB) (1–3). An association between insomnia and OSA was first
described in 1973 (4). Some studies have shown a high prevalence (39 to 55 %) of insomnia
symptoms in patients with OSA in the past (1, 5–7). Insomnia and OSA both share a number of
negative consequences, which include increased cardiovascular risk and decreased health-related
quality of life (QOL) (8–11). The two disorders combined show an increase in cumulativemorbidity
and an overall greater illness severity (5). It is believed that OSA could either cause insomnia or
exacerbate it (12).
Some studies suggest that the presence of insomnia symptoms may reduce the positive airway
pressure (PAP)-compliance in OSA patients (13–16). On the other hand, some studies give reason
to believe that insomnia refractory to usual cognitive behavioral therapy (CBTI) may be associated
with coexistent SDB. It is also suggested that adequate OSA-therapy leads to improvement
of insomnia symptoms (13). Nonetheless, there is still considerable controversy regarding
management decisions in this group of patients. The correlation between OSA severity and severity
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of co-existent insomnia is weak. This fact in combination with
a usually indistinguishable clinical presentation of comorbid
insomnia and obstructive sleep apnea (COMISA) (17) and
insomnia alone raises questions as to whether COMISA is a
separate distinct clinical entity at all (18).
To date, themost recent reviews on this topic are from the year
2010 and 2017. In their systematic review from the year 2010,
Luyster et al. suggested that the combination of both CBTI and
OSA treatment resulted in greater improvements in insomnia
than did either CBTI or OSA treatment alone (13). Sweetman
et al. reviewed research focusing on prevalence, characteristics
and theoretical mechanistic relationships in COMISA patients
(17). They emphasize on different insomnia entities, stating
that insomnia and its symptoms in COMISA could either be
secondary to OSA or an independent entity. Thus, depending on
its entity, COMISA needs to be treated differently. However, the
differentiation between independent and secondary COMISA is
difficult.
We extended the information of these two studies by
reviewing literature from 2010 to 2017 focusing on the following
aspects:
Our primary research question was to review observational
or interventional studies about the association between PAP-
therapy and CBTI as exposures and insomnia as the outcome in
COMISA patients. A secondary aim was reviewing observational
or interventional studies about insomnia as exposure and
adherence to PAP-therapy as the outcome. A tertiary aim was
reviewing the comparators of PAP-therapy and CBTI on the one
hand and adherence to PAP-therapy on the other, in order to
make recommendations for future research.
METHODS
Literature Search
Eligible studies included populations with OSA and insomnia.
Acceptable definitions of OSA were an apnea-hypopnea-
index (AHI) ≥5 events/hour or a respiratory-distress-index
(RDI) of ≥5 events/hour. Acceptable definitions of insomnia
were an insomnia severity index (ISI) ≥ 14 points, a
Regensburg-Insomnia-Score (RIS) ≥ 14 points or a Nordic sleep
questionnaire ≥ 4 points on one of the insomnia questions.
Eligible studies included interventions of PAP and/or CBTI
starting at study beginning or prior. Pharmacological and
surgical interventions were out of the scope of this review.
Comparators were presence vs. absence or different levels of
OSA or insomnia. Although the focus of this review was the
direct association between OSA and insomnia, outcomes such
as adherence to the intervention were also eligible, as long as
they referred to OSA or insomnia. Outcomes related to other
chronic conditions, such as dementia or multiple sclerosis, were
an exclusion criterion. Eligible study designs were interventional
studies as well as cohort studies, case control studies and case
series.
The Medline terms for the identification of literature were
[(insomnia asv) OR (insomnia pap) OR (insomnia apap) OR
(insomnia cpap) OR (CBTI OSA) OR (cognitive behavioral
therapy OSA insomnia) OR (CBTI sleep apnea insomnia) OR
(cognitive behavioral therapy sleep apnea insomnia)] AND
(“2010/01/01”[PDat]: “2017/10/15”[PDat]). During the selection
process, the first and third author classified the search results
according to a protocol established by the second author. They
performed a title/abstract screening followed by a full text
screening and met after each round to solve disagreement
regarding eligibility and main reason for exclusion in consensus.
The study selection protocol followed the PICOS algorithm
(population, interventions, comparators, outcomes, and study
designs). The language was restricted to English or German
articles. The first and third author screened the selected articles
for further eligible studies.
Extraction and Presentation of Data
Following a PICOS-based protocol, the first and second author
extracted data about methods and results of the original
articles and presented it in two tables. In case of multiple
exposures/interventions and outcomes related to OSA or
insomnia as well as multiple analyses of one association, they
presented the data most related to the primary objective of this
systematic review, which was the direct association between OSA
and insomnia. Second, they favored exposures/interventions
clearly preceding the outcome. Third, they preferred results from
thorough analyses with straightforward association measures
supported by confidence intervals and p-values. Based on
quantitative information, the authors made an effort to provide
their own interpretation of the results rather than blindly
repeating statements from the discussions of the original articles.
They solved disagreements between each other in consensus and
summarized interpretational deviations from the conclusions of
the original articles in the text. They summarized characteristics
of the original samples with standardmeasures. Due to amajority
of observational original studies, they followed the MOOSE
checklist [(19); Supplementary Material] and completed it with
the PRISMA checklist (20), if necessary.
RESULTS
Methodological Issues
Of 130 records identified in Medline, 12 studies were eligible
(Figure 1). Additional handsearch revealed another study eligible
to our research question (21). Of these 13 studies, six addressed
our primary research question (21–26) and the other seven
analyzed the association between insomnia as exposure and
adherence to PAP as outcome (12, 27–32). To define OSA,
seven studies used the AHI with three different cutoffs, three
used the RDI with two cutoffs, one study used both RDI and
AHI, and two relied on the international classification of sleep
disorders. In order to define insomnia, seven studies used the
Insomnia Severity Score (ISS) with three different definitions.
Two studies used the Basic Nordic sleep questionnaire, two relied
on the international classification of sleep disorders and one
study used the RIS. Ten studies had PAP-therapy as the only
intervention, two studies investigated CBTI alone, and one study
examined both therapies. Four studies differentiated between
initial, middle and late insomnia (Table 1). Three of the six
studies that addressed our primary research question and two of
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FIGURE 1 | Literature selection process.
the seven studies that analyzed the association between insomnia
and adherence to PAP used more eligibility criteria than OSA
and insomnia to define their populations. In the former group,
one study included only military veterans with a mini mental
state ≥24 points and without serious physical or mental health
issues (24), one included only patients with psychophysiological
risk factors of insomnia such as poor sleep hygiene (25), and
one excluded other sleep disorders such as narcolepsy (26). In
the latter group, two included only military veterans without
previous OSA-surgery or oxygen supplementation (27, 30). Two
studies included participants from the icelandic sleep study for
different objectives (28, 32). Their data probably overlapped.
Outcomes
Of the six studies addressing our primary research question, four
indeed analyzed the effect of PAP, i.e., OSA-therapy, on insomnia
(22, 23, 25, 26), while two studies analyzed the direct effect
of OSA on insomnia comparing two groups without PAP, and
with equal CBTI for both groups (21, 24) . Of the four studies
analyzing the effect of PAP on insomnia, three measured the
exposure in minutes per night and one used no control. Of the
former three studies, two used a cut-off, namely 240min PAP-use
per night and 171min per night (22, 25), and the third looked
at the exposure continuously (23). The second only reported
results for participants above the cut-off stating that those below
were not statistically significant (26). One defined the outcome
as improvement of the ISI of 9 points (22), one defined it as
follow-up subscale score of <4 of the ISI (23), and one reported
no definition. The last differentiated between initial, middle, and
late insomnia (25). The first found that adherence to OSA therapy
increased the chance of successful insomnia therapy by 1.1 times
(22), the second found that patients with persistent insomnia
have 72min less PAP-use per night (23), and the study omitting
the results for the control found improvements of 0.7 standard
deviations in initial, 0.9 in middle, and 0.6 in late insomnia
(25). The study without control for the exposure found that PAP
and/or CBTI decreased insomnia by 0.55 standard deviations
and the total wake time by 41min on the average (26). The
findings were statistically significant in the second and the third
of these four studies. The studies analyzing the direct effect
of OSA on insomnia were the only interventional studies that
fitted our eligibility criteria. The first one found that insomnia
decreased more in participants randomized to sleep education
than those randomized to CBTI (24). Besides, it found that
the difference between sleep education and CBTI was 21min
higher in participants with mild OSA than in those without.
This interaction was not statistically significant (Table 2) (24).
The second study dealing with CBTI found that CBTI decreases
insomnia by 2 points less and increases sleep efficiency by 1.8%
more in patients with OSA compared to those without (21).
Generally, the robust clinical improvements with CBTI were
comparable between those with insomnia alone and the COMISA
patients.
In the six studies addressing our primary research question,
the proportion of women ranged between 3.0 and 66.9%, the
mean age ranged between 47.5 and 72.2 years, and the AHI/RDI
ranged between 9.4 and 45.0 events per hour. In the seven
studies addressing the effects of insomnia on adherence to PAP,
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the proportion of women ranged between 6.0 and 43.5%, the
mean age ranged between 53.6 and 59.0 years, and the AHI/RDI
ranged between 39.0 and 45.5 events per hour. Three of them
differentiated between initial, middle and late insomnia (27, 28,
32). Four studies compared presence of insomnia according to
criteria summarized above vs. absence of insomnia (12, 27, 28,
32). The other three looked at the exposure as a continuous
predictor (29–31). With respect to the outcome, five of seven
studies measured PAP-adherence in minutes per night (12, 14,
28–30), one defined non-adherers, attempters, and adherers by
cluster analysis (31), and one compared participants quitting the
therapy before 1 year after initiation with those quitting later and
excluded the continuers (32). Of the first five, three looked at
insomnia continuously, where one found that insomnia decreases
the adherence by 24min per night (12), one found that one
standard deviation of insomnia diminishes it by 156min per
night (29), and the last one found that the standard deviation
decreases it by 17min per night (30). Two divided insomnia
into three phenotypes, where one found that initial insomnia
decreases the chances of adherence by 1.05, middle insomnia by
1.23 and that late insomnia increases the chances by 1.07 (27),
and one found that initial and late insomnia almost halves the
chances of adherence, while middle insomnia has no effect (28).
The study that defined adherence by cluster analysis found that
insomnia has no effect on being an attempter and decreases the
chance of being an adherer by 1.1. The last study found that late
and middle insomnia has no influence on being an early-quitter,
while initial insomnia doubles the chances (31) (Table 2).
DISCUSSION
Two of four studies reporting controlled results are too few to
draw well-supported conclusions on the influence of the OSA-
therapy on insomnia (22, 23), and two clinical trials reporting
an interaction between OSA and the effect of insomnia-therapy
on insomnia is little evidence for or against the influence of
OSA itself on insomnia (21, 24). While the first of the two
controlled observational studies found a very small effect of
OSA-therapy on insomnia (OR 1.1, 95%CI: 1.0 to 1.2) (22),
the second found that increasing PAP-use by 72min per night
may favor the improvement of insomnia (p = 0.02) (23). It
remains uncertain, however, how likely this additional PAP-use
might improve insomnia. One of the clinical trials found that
the presence of OSA increases insomnia by 21min per night,
more precisely, it detected the superiority of sleep education
over CBTI that increases so much if the patient has OSA
(24). Reporting this interaction, the direct effect of OSA on
insomnia was omitted. The 21min are neither clinically relevant
nor statistically significant (P = 0.58). Altogether, the small
number of studies plus the inconsistency and incompleteness of
the results provide little evidence about a potential association
between OSA-therapy and insomnia.
With seven controlled observational studies, the effect of
insomnia on PAP-adherence is better investigated than the
effect of OSA-therapy on insomnia. However, four studies with
clinically relevant associations [156min decrease of adherence
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per night, 1.23 lower, and halved chances of being adherent
(27–29, 32)] against three studies with negligible associations
(24 and 17min decrease per night, 1.1 lower chances) (12,
30, 31) favor neither one conclusion nor the other. The
strongest associations (halved chances of being adherent) favor
a decrease of PAP-adherence caused by insomnia. As all studies
distinguishing between initial, middle and late insomnia found
very different associations regarding these three entities, this
distinction seems important (25, 27, 28, 32) . One study found
clinical relevance in middle insomnia only, which decreased
adherence (OR 1.2) (14), one found high clinical relevance in
initial and late insomnia, which decreased adherence (OR 2) (28),
and one found high clinical relevance again for initial insomnia,
which decreased adherence (OR 2) (32). Taken together, the
association with late insomnia seems the strongest. However, the
evidence is again too small for conclusions.
At study level, heterogeneous populations, distinct definitions
and measurements of exposures/interventions, outcomes and
controls, and different analyses might be some reasons for the
heterogeneity of the findings. The thirteen studies used seven
different definitions of OSA and eight different definitions of
insomnia. However, most of these definitions match well, and
most studies used PAP-therapy. The most striking heterogeneity
in terms of populations is that three studies included only
military veterans with a percentage of women ranging between
three and six vs. 12 and 62 in the other studies (24, 30, 31).
Two of these three populations had a similar age distribution
as the other studies, and one was clearly elder (72 years with
a standard deviation of eight) (24). The most probable reason
for that was the fact that this study sampled insomnia patients
and screened them for OSA, while the other studies sampled
OSA-patients and screened them for insomnia. In conclusion,
the populations were heterogeneous but still comparable. The
fact that three studies measuring adherence to PAP-therapy as
exposure and the seven measuring adherence to PAP-therapy
as outcome used seven very different definitions of adherence
to PAP-therapy compromised the comparability more than the
different populations. The remaining three used CBTI and a mix
of CBTI and OSA.
At review level, two main limitations may contribute to
the small number of studies and to the incompleteness of
the results. First, we relied on Medline as the only search
engine; second, we had no contact with the authors when
information was missing or our and their interpretation of the
findings differed. However, our structured approach included
more than 100 working hours per person in a thorough section
of literature and data extraction following the PICOS algorithm.
A publication period ranging from the last original article of
the updated review by Luyster et al. up to 6 months before
identifying the literature reduced the publication bias, because
search engines rapidly process publications that are easy to
find, but need several months to process publications with
lower impact factor. The entire search was double-checked and
two investigators discussed and interpreted all findings together
without merely relying on statements from the discussions of
the original articles. While they did so, they found that the cited
research confirmed the completeness of the identified literature.
A further strength at review level at the expense of the number
of eligible studies was a satisfactory definition of the population
as inclusion criterion. It resulted in the exclusion of studies
confirming insomnia by superficial questions such as “do you
have insomnia.” Overall, the ratio between efforts to improve
quality on the one hand and availability information on the other
was considerable.
The review by Luyster that we updated found two studies with
OSA-therapy as exposure and insomnia as outcome, as well as
one study with insomnia therapy as intervention and adherence
to PAP-therapy as the outcome (13). As it used no defined
publication period as inclusion criterion, the period was probably
longer than ours. Nevertheless, the previous review found fewer
studies fitting our other criteria than we did, which also points
out the comprehensiveness of the literature that we identified.
Of the first two studies, one was a pilot study attaining a non-
clinical level of insomnia in eight of 17 patients with CBTI alone.
After adding OSA-therapy, further seven of the remaining nine
patients attained a non-clinical level (33). In other words, this
before after study, just as two of our four studies, had no control.
The other found that the combination of OSA-surgery and CBTI
was the best option for COMISA (34). This surgical study was out
of the scope of our PAP-review. The third study found regular
PAP-use in 26 of 39 patients assigned to a daytime sleep medical
procedure compared to 14 of 60 historical controls (35). This very
impressive finding corresponds to an OR of six and makes our
ORs of two for the effect of initial and late insomnia on adherence
and for the effect of initial insomnia on non-adherence looking
small. It is surprising, because the treatment of the disease in
the best case annuls 100% of the impact of the disease itself.
It would have been interesting to know how the daytime sleep
medical procedure influenced initial, middle, and late insomnia
itself. In other words, we found thin evidence but the evidence of
the studies we updated was even thinner. An effect of insomnia
on adherence to PAP-therapy is probable, however.
The more recent review by Sweetman et al. found in total
8 studies dealing with either CBTI alone or with combined
treatments in COMISA patients including drug studies, case
studies and studies dating back up to the year 2001 (17). One
study in the review by Sweetman et al matched our well-defined
eligibility criteria, namely the study by Lack et al. presented
at SLEEP in 2011. They found that independently of OSA the
treatment of insomnia decreased the sleep latency by 36min and
increased the total sleep time by 0.7 h and the sleep efficiency by
18% (36).
Given the sparse evidence and the inconsistency of the current
evidence, more research is needed in this topic. Nonetheless, the
general conclusion from the study by Sweetman et al. is that
both groups, namely patients with insomnia only and COMISA,
benefited in their sleep and daytime measures from CBTi about
equally well (21). Thus having co-morbid OSA did not impair the
treatment of the insomnia in the COMISA group.
Several studies investigated whether the presences of
comorbid insomnia impaired PAP-adherence but the
inconsistent results make it difficult to conclude that comorbid
insomnia impairs PAP adherence. To answer this question a
randomized controlled trial should be performed in the future
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with a group of patients treated with PAP alone and another
group treated with a combination of PAP and CBTI, e.g., in the
form suggested by Crawford et al. (37).
There is evidence that insomnia can be treated also in
COMISA patients with CBTI (21). That, in itself may reduce
the disease burden and justify the use of CBTI, even if it does
not improve PAP adherence in the OSA treatment. However,
two studies are few and more studies are needed. Especially
studies pre-treating or concurrently treating the insomnia in
COMISA patients deserve to be thoroughly assessed. Even more,
the findings of our review are inconsistent with those of Luyster
et al., who found one study with a remarkable effect of CBTI in
OSA patients, namely an increased PAP-adherence with CBTI in
OSA with an OR of 6 (35).
As a few studies suggest that OSA-treatment has an impact
on insomnia, an immediate PAP-therapy and reevaluation of
insomnia symptoms in the course of it, might lead to insomnia
improvement or abandonment of CBTI due to subclinical
severity scores.
The revision of studies on PAP-adherence revealed several
attempts to build adherence groups, which is an indicator
of missing thresholds for PAP-adherence evaluation. We
recommend a definition of adherence to PAP-therapy in hours
per night or nights of use per months, since it would increase the
comparability of the results and might ease the decision whether
or not an intervention is reasonable.
The time pattern of insomnia symptoms, namely middle
insomnia with awakenings during the nights, initial insomnia
with difficulties to fall asleep and late insomnia, which is to say
early morning awakenings, seem to be entirely different COMISA
entities that react differently to PAP-therapy and might have
different effects on PAP-therapy-adherence. Such a phenotypic
classification may prove to be quite useful in future studies in
order to provide personalized care in this broad group of patients.
Reviewing the literature, it has been interesting to see, that
pneumologists and sleep physicians put emphasis on apneic
events, whereas neurologists and psychologists focused more
on insomnia criteria. Therefore, we suggest an interdisciplinary
approach in the treatment of COMISA patients in order to reflect
on both entities equally.
Due to the above mentioned inconsistency of study designs
and results the temporary evidence level is not yet sufficient for
a meta-analysis on COMISA therapy. In order to promote
personalized management to COMISA patients and to
perform meta-analyses in the future, it might be advisable
to use study designs that specify both insomnia in the time
domain (initial, middle, late) and that consider CBTI as
well as PAP-therapy regimens in distinct combined patient
phenotypes.
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